Entries by Redazione

President Carrozza visits HT and Polo Milano 4

During her visit to Milan 4, the President was accompanied by Daniela Corda and Sabato D’Auria, respectively directors of the Departments of Biomedical Sciences and Bioagri-food, and she had the opportunity to know the Institute of Biomedical Technologies directed by Gianluca De Bellis (Itb) , which hosts important infrastructures of genomics, proteomics and bioinformatics, and […]

IGM-IFOM Joint Seminars – Giorgia Zadra

May 20th, 2021 at 14:30 Giorgia Zadra, Researcher at the IGM, on: The Fats and The Furious Metabolic rewiring fuels aggressive prostate cancer: clinical implications

Interleukin-6 neutralization ameliorates symptoms in prematurely aged mice.

This work identifies tocilizumab, a neutralizing antibody already exploited in clinical applications, as a valuable therapeutic tool in Hutchinson-Gilford progeria, a disease that causes premature ageing. Data here reported further suggest to explore tocilizumab as a potential treatment for aging-related disorders. The study has been designed and coordinated by CNR IGM Bologna Unit.   Squarzoni […]

Joining European Scientific Forces to Face Pandemics

Despite the international guidelines on the containment of the COVID-19 pandemic, the European scientific community was not sufficiently prepared to coordinate scientific efforts. To improve preparedness for future pandemics, nine groups of scientists already funded by the European program for Cooperation in Science and Technology (COST), coordinated by Chiara Rignati from Turin University, joined in […]

IGM-IFOM Joint Seminars – Marco Foiani

The next IGM-IFOM seminar will ben on May 6th, at 14:30 The speaker Marco Foiani, Scientific Director of IFOM, entitled:  “Mechanism controlling Genome and Nuclear Integrity”

DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects

Mutations in BRCA1 and BRCA2 tumor suppressor genes predispose individuals to breast and ovarian cancers. These cancers are treated in the clinic with platinum drugs and inhibitors of polyADP-ribose polymerase (PARP), which cause lesions requiring homologous recombination repair activities mediated by BRCA1 and BRCA2. However, BRCA1 and BRCA2 tumors often acquire resistance to chemotherapy, either […]